In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 

Association between bleeding after acute coronary syndrome and newly diagnosed cancers

Session Poster Session 1

Speaker Isabel Munoz Pousa

Congress : ESC Congress 2019

  • Topic : cardiovascular disease in special populations
  • Sub-topic : Cardio-Oncology
  • Session type : Poster Session
  • FP Number : P677

Authors : I Munoz Pousa (Vigo,ES), S Raposeiras Roubin (Vigo,ES), E Abu-Assi (Vigo,ES), M Cespon Fernandez (Vigo,ES), B Caneiro Queija (Vigo,ES), R Cobas Paz (Vigo,ES), E Lopez Rodriguez (Vigo,ES), L Perez Casares (Vigo,ES), K Jamhour Chelh (Vigo,ES), M Castineiras Busto (Vigo,ES), S Fernandez Barbeira (Vigo,ES), G Bastos Fernandez (Vigo,ES), R Bilbao Quesada (Vigo,ES), A Iniguez Romo (Vigo,ES)

Authors:
I Munoz Pousa1 , S Raposeiras Roubin1 , E Abu-Assi1 , M Cespon Fernandez1 , B Caneiro Queija1 , R Cobas Paz1 , E Lopez Rodriguez1 , L Perez Casares1 , K Jamhour Chelh1 , M Castineiras Busto1 , S Fernandez Barbeira1 , G Bastos Fernandez1 , R Bilbao Quesada1 , A Iniguez Romo1 , 1Hospital Universitario Alvaro Cunqueiro - Vigo - Spain ,

Citation:

Introduction. There is a growing body of evidence on the incidence and negative prognostic impact of post-discharge hemorrhagic complications after acute coronary syndrome (ACS). The aim of this study was to assess the association of post-discharge bleeding with new cancer diagnosis after ACS.

Methods. Data from a single-center registry of 3,644 ACS patients discharged with dual antiplatelet therapy (DAPT) were used to investigate the association between post-discharge bleeding and diagnosis of cancer.  The adjusted effect of bleeding as time-varying covariate on subsequent cancer diagnosis was assessed using Cox regression models. Positive predictive values (PPVs) of bleeding for cancer diagnosis were calculated.

Results. During a median follow-up of 56.2 months, bleeding events were documented in 1,215 patients and new cancers in 227 patients. After multivariable adjustment, post-discharge bleeding was associated with cancer diagnosis (adjusted HR 3.43, 95% CI 2.62-4.50), but only spontaneous bleeding (adjusted HR=4.38, 95% CI 3.31-5.79). This association was stronger as the severity of the bleeding increased (HR= 1.52, 4.88, 7.30, and 12.29, for BARC type 1, 2, 3a, and 3b bleeding, respectively). With respect to the specific location of bleeding for diagnosis of cancer, only gastrointestinal, genitourinary and bronchopulmonary bleeding result strongly associated with site-specific cancers [Table]. No differences in the adjusted risk of cancer were found for those post-discharge bleedings that happened on-DAPT versus off-DAPT (HR for on-DAPT bleeding vs off-DAPT bleeding: 1.05, 95% CI 0.69-1.62; p=0.832). PPV for cancer diagnosis of post-discharge bleeding was 7.7%. (21.9% for genitourinary bleeding, 18.6% for bronchopulmonary bleeding, 5.8% for gastrointestinal bleeding, and 2.3% for other bleedings). Median time from bleeding to cancer was 4.6 months.

Conclusions. Spontaneous post-discharge bleeding in ACS patients is strongly associated with subsequent cancer diagnosis within the first 6 months. A prompt evaluation of bleeding could be useful for enabling an early detection of cancer in these patients.

VARIABLES HR 95% CI P
ANY BLEEDING 3.43 2.62-4.50 <0.001
BLEEDING SEVERITY

BARC 1 (n=622)

BARC 2 (n=436)

BARC 3A (n=71)

BARC 3B (n=46)

BARC 3C (n=37)

1.52

4.88

7.30

12.29

3.07

0.96-2.43

3.48-6.85

3.68-14.46

5.59-26.98

0.73-12.84

0.074

<0.001

<0.001

<0.001

0.125

BLEEDING SPONTANEITY

SPONTANEOUS (n=827)

TRAUMATIC BLEEDING (n=389)

4.38

1.29

3.31-5.79

0.69-2.41

<0.001

0.418

BLEEDING LOCATION

GASTROINTESTINAL (GI; n=327)

GENITOURINARY (GU; n=228)

BRONCHOPULMONARY (BP; n=56)

OTHERS (No GI, no GU, no BP; n=605)

3.78

8.63

4.26

1.32

2.51-5.71

5.91-12.59

1.85-9.84

0.81-2.18

<0.001

<0.001

0.001

0.264

BLEENDING WITH DAPT

BLEEDING ON-DAPT

BLEEDING OF-DAPT

3.50

3.34

2.56-4.80

2.29-4.89

<0.001

<0.001

This content is currently on FREE ACCESS, enjoy another 101 days of free consultation

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are